Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia Pty Ltd

Bristol-Myers Squibb Australia trial registry — 93 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Bristol-Myers Squibb Australia clinical trials

Registry index of 93 ClinicalTrials.gov studies linked to Bristol-Myers Squibb Australia programs — each row shows trial ID, program name, phase, status, and indication.

Bristol-Myers Squibb Australia trial registry — 93 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Bristol-Myers Squibb Australia.

  1. IM101-863 — Phase 3

    Clinical update

  2. IM011-075 — Phase 3

    Clinical update

  3. IM011-054 — Phase 3

    Clinical update

  4. CA224-047 — Phase 3

    Clinical update

  5. CA209-577 — Phase 3

    Clinical update

  6. CA111-001 — Phase 1

    Clinical update

  7. CN0140003 — Phase 1

    Clinical update

  8. CA258-0001 — Phase 2

    Clinical update

Trial registry

93 studies
  36. 2023-508954-25-00

    CA043-001

    Phase 2 active small_molecule

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    CTIS ↗
  45. 2024-510784-36-00

    CA180-226

    Phase 2 active small_molecule

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    CTIS ↗
  58. 2024-516540-25-00

    CA209-032

    Phase 2 active small_molecule

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    CTIS ↗
  90. 2025-524334-26-01

    CA243-0001

    Phase 1 active other

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.